

NDG1 siRNA (h): sc-95087

BACKGROUND

NDG1, also known as KHDC1 (KH homology domain containing 1), is a 237 amino acid multi-pass membrane protein that belongs to the KHDC1 family. Existing as two alternatively spliced isoforms, NDG1 contains one KH domain and is encoded by a gene that maps to human chromosome 6q13. Chromosome 6 contains 170 million base pairs and comprises nearly 6% of the human genome. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer, suggesting the presence of a cancer susceptibility locus. Additionally, porphyria cutanea tarda, Parkinson's disease, Stickler syndrome, maple syrup urine disease and a susceptibility to bipolar disorder are all associated with genes that map to chromosome 6.

REFERENCES

1. Zneimer, S.M., Lau, K.S., Eddy, R.L., Shows, T.B., Chuang, J.L., Chuang, D.T. and Cox, R.P. 1991. Regional assignment of two genes of the human branched-chain α -keto acid dehydrogenase complex: the E1 β gene (BCKDHB) to chromosome 6p21-22 and the E2 gene (DBT) to chromosome 1p31. *Genomics* 10: 740-747.
2. Brunner, H.G., van Beersum, S.E., Warman, M.L., Olsen, B.R., Ropers, H.H. and Mariman, E.C. 1994. A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. *Hum. Mol. Genet.* 3: 1561-1564.
3. Edelmann, L., Wasserstein, M.P., Kornreich, R., Sansaricq, C., Snyderman, S.E. and Diaz, G.A. 2001. Maple syrup urine disease: identification and carrier-frequency determination of a novel founder mutation in the Ashkenazi Jewish population. *Am. J. Hum. Genet.* 69: 863-868.
4. Cesari, R., Martin, E.S., Calin, G.A., Pentimalli, F., Bichi, R., McAdams, H., Trapasso, F., Drusco, A., Shimizu, M., Masciullo, V., D'Andrilli, G., Scambia, G., Picchio, M.C., Alder, H., Godwin, A.K. and Croce, C.M. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc. Natl. Acad. Sci. USA* 100: 5956-5961.
5. Bläker, H., Mechttersheimer, G., Sutter, C., Hertkorn, C., Kern, M.A., Rieker, R.J., Penzel, R., Schirmacher, P. and Kloor, M. 2008. Recurrent deletions at 6q in early age of onset non-HNPCC- and non-FAP-associated intestinal carcinomas. Evidence for a novel cancer susceptibility locus at 6q14-q22. *Genes Chromosomes Cancer* 47: 159-164.
6. Fan, J., Ionita-Laza, I., McQueen, M.B., Devlin, B., Purcell, S., Faraone, S.V., Allen, M.H., Bowden, C.L., Calabrese, J.R., Fossey, M.D., Friedman, E.S., Gyulai, L., Hauser, P., Ketter, T.B., Marangell, L.B., Miklowitz, D.J., et al. 2010. Linkage disequilibrium mapping of the chromosome 6q21-22.31 bipolar I disorder susceptibility locus. *Am. J. Med. Genet. B Neuropsychiatr. Genet.* 153B: 29-37.
7. Jalil, S., Grady, J.J., Lee, C. and Anderson, K.E. 2010. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. *Clin. Gastroenterol. Hepatol.* 8: 297-302, 302.e1.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: KHDC1 (human) mapping to 6q13.

PRODUCT

NDG1 siRNA (h) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see NDG1 shRNA Plasmid (h): sc-95087-SH and NDG1 shRNA (h) Lentiviral Particles: sc-95087-V as alternate gene silencing products.

For independent verification of NDG1 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-95087A and sc-95087B.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

NDG1 siRNA (h) is recommended for the inhibition of NDG1 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor NDG1 gene expression knockdown using RT-PCR Primer: NDG1 (h)-PR: sc-95087-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.